![]() |
市场调查报告书
商品编码
1831901
2025 年至 2033 年重组 DNA 技术市场报告(按产品、组件、应用、最终用户和地区)Recombinant DNA Technology Market Report by Product, Component, Application, End User, and Region 2025-2033 |
2024年,全球重组DNA技术市场规模达7,962亿美元。展望未来, IMARC Group预计到2033年,该市场规模将达到1.1434兆美元,2025-2033年期间的复合年增长率(CAGR)为3.9%。基因工程和生物技术的持续进步、生物製药需求的不断增长、个人化医疗的日益普及以及慢性病盛行率的上升,是推动市场成长的主要因素。
生物製药需求不断成长
对单株抗体、疫苗和胰岛素等生物製药产品日益增长的需求是主要驱动力。例如,根据IMARC的数据,全球生物製药市场规模在2023年达到3,005亿美元。展望未来, IMARC Group预计到2032年,市场规模将达到6,439亿美元,2024-2032年期间的复合年增长率(CAGR)为8.6%。重组DNA技术在这些产品的生产中至关重要,而这些产品对于治疗各种慢性疾病至关重要。预计这些因素将在未来几年推动重组DNA技术市场的发展。
慢性病盛行率不断上升
癌症、糖尿病和心血管疾病等慢性疾病的日益普及是推动市场成长的重要因素之一。例如,根据IDF糖尿病地图集(2021),20至79岁的成年人中10.5%患有糖尿病。此外,到2045年,每八人中就有一人(约7.83亿人)将罹患糖尿病,增幅达46%。重组DNA技术能够生产必需的治疗性蛋白质和激素,例如用于糖尿病管理的胰岛素和用于贫血治疗的促红血球生成素。这些因素正在进一步积极影响重组DNA技术产业市场。
技术进步
CRISPR 和其他基因编辑工具等持续的技术创新,正在提升重组 DNA 技术的精准度和应用范围,进而推动市场扩张。例如,2024 年 8 月,一群德国研究人员开发了一种增强型 CRISPR(成簇规律间隔短回文重复序列)技术,以解决和改善针对血液肿瘤和实体瘤的 CAR-T 细胞疗法中现有的障碍。 CRISPR 是一项独特的技术,它使遗传学家和医学研究人员能够透过移除、插入或改变 DNA 序列来编辑基因组的某些部分,从而提升重组 DNA 技术系统市场的收入。
The global recombinant DNA technology market size reached USD 796.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 1,143.4 Billion by 2033, exhibiting a growth rate (CAGR) of 3.9% during 2025-2033. The ongoing advancements in genetic engineering and biotechnology, the growing demand for biopharmaceuticals, increasing shift towards personalized medicines, and the rising prevalence of chronic diseases are primarily driving the market's growth.
Rising Demand for Biopharmaceuticals
The rising demand for biopharmaceuticals, including monoclonal antibodies, vaccines, and insulin, is a major driver. For instance, according to IMARC, the global biopharmaceutical market size reached US$ 300.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 643.9 Billion by 2032, exhibiting a growth rate (CAGR) of 8.6% during 2024-2032. Recombinant DNA technology is pivotal in the production of these products, which are essential for treating various chronic diseases. These factors are expected to propel the recombinant DNA technology market in the coming years.
Increasing Prevalence of Chronic Diseases
The increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular diseases, is one of the significant factors driving the market's growth. For instance, according to the IDF Diabetes Atlas (2021), 10.5% of adults aged 20 to 79 suffer from diabetes. Also, by 2045, one in every eight persons, or roughly 783 million, will have diabetes, representing a 46% rise. Recombinant DNA technology enables the production of essential therapeutic proteins and hormones, such as insulin for diabetes management and erythropoietin for anemia treatment. These factors are further positively influencing the recombinant DNA technology industry market.
Technological Advancements
Continuous technological innovations, such as CRISPR and other gene-editing tools, are enhancing the precision and application scope of recombinant DNA technology, driving the market expansion. For instance, in August 2024, a group of German researchers developed an enhanced CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technique to solve and improve existing obstacles in CAR-T cell therapy that targets both blood and solid tumors. CRISPR is a unique technology that enables geneticists and medical researchers to edit portions of the genome by removing, inserting, or changing DNA sequences, thereby boosting the recombinant DNA technology systems market revenue.
According to the recombinant DNA technology market outlook, recombinant DNA technology enables the development of gene therapies to treat genetic disorders like cystic fibrosis, hemophilia, and muscular dystrophy. This technology has revolutionized the production of human insulin, making it more accessible for diabetic patients. While crops like Bt cotton, Roundup Ready soybeans, and Golden Rice have been developed using rDNA technology to enhance resistance to pests, herbicides, and to improve nutritional content.
According to the recombinant DNA technology market overview, an expression system refers to the host organism and the molecular machinery used to produce recombinant proteins. It includes the host cells, the vectors, and the regulatory sequences necessary for gene expression. While a cloning vector is a DNA molecule used to carry foreign genetic material into a host cell, where it can be replicated and/or expressed. It is used in the development of genetically modified crops with desirable traits such as pest resistance and improved nutritional content.
Recombinant DNA technology is used to develop genetically modified (GM) crops with desirable traits such as increased yield, pest resistance, herbicide tolerance, and improved nutritional content. This is crucial for meeting the food demands of a growing global population. Apart from this, in health and disease, it enables the production of insulin, growth hormones, monoclonal antibodies, and vaccines. The demand for effective and affordable biopharmaceuticals drives this sector. Besides this, it is also used to engineer microorganisms that can break down pollutants and toxins in the environment. This helps in cleaning up oil spills, heavy metals, and other environmental contaminants.
In biotechnology and pharmaceutical companies, recombinant DNA technology is used to produce human insulin in bacteria, which is a major advancement over previous methods using animal insulin. Companies use rDNA to develop monoclonal antibodies for the treatment of various diseases, including cancer and autoimmune disorders. While government research institutes like the CDC use rDNA technology to monitor and study pathogens, enabling rapid response to outbreaks and epidemics.
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.
According to the recombinant DNA technology market statistics, North America is one of the prominent regions for rDNA technology due to significant investments in biotechnology and pharmaceuticals. Moreover, Europe has a well-established biotechnology sector, particularly in countries like Germany, France, and the UK. The growth of the European region is driven by the strong collaboration between academic institutions, research institutes, and industry.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include: